Hatzakis Kostas D, Froudarakis Marios E, Bouros Demosthenes, Tzanakis Nikolaos, Karkavitsas Nikolaos, Siafakas Nikolaos M
Department of Pneumonology, University of Crete Medical School, Heraklion, Greece.
Respiration. 2002;69(1):25-9. doi: 10.1159/000049366.
The role of tumor markers in the diagnosis and prognosis of lung cancer is under investigation.
The aim of this study was to investigate the diagnostic and prognostic significance of pre-therapeutic levels of various serum tumor markers, CYFRA 21-1, neuron-specific enolase (NSE), tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), CA 125 and squamous cell carcinoma antigen (SCCAg), in patients with lung cancer.
We studied 102 consecutive patients (mean age 65.2 +/- 11 years) with newly diagnosed lung cancer (96 males, 94%, with a mean age of 66.3 +/-10.5 years). All patients had a 5-year follow-up. Measurements of the serum tumor markers were performed on initial diagnosis.
Eighty-four patients (82%) had non-small-cell lung cancer (NSCLC) and 18 (18%) small-cell lung cancer (SCLC). From the 84 patients with NSCLC, 34 patients (33%) had squamous-cell lung cancer, 23 (22%) adenocarcinoma and 23 (22%) large-cell carcinomas. The overall median survival was 8.5 months. All SCLC patients had extensive disease with a median survival of 10.1 months and NSCLC patients of 8.4 months. Significant differences in the mean values of NSE and CYFRA 21-1 were observed between SCLC and NSCLC. In NSCLC, CYFRA 21-1, TPA, CA 125 and SCCAg serum levels were related to the stage of the disease at diagnosis, and CYFRA 21-1, NSE, TPA and CA-125 were related to a poor outcome. None of the above tumor markers was related to survival in the SCLC group.
CYFRA 21-1 and NSE may help to differentiate cell types in lung cancer patients. Also, CYFRA 21-1 with TPA and CA 125 may provide useful information regarding the staging of the disease at diagnosis and the prognosis of patients with NSCLC.
肿瘤标志物在肺癌诊断及预后中的作用正在研究中。
本研究旨在探讨治疗前不同血清肿瘤标志物，即细胞角蛋白19片段（CYFRA 21-1）、神经元特异性烯醇化酶（NSE）、组织多肽抗原（TPA）、癌胚抗原（CEA）、糖类抗原125（CA 125）和鳞状细胞癌抗原（SCCAg）水平在肺癌患者中的诊断及预后意义。
我们研究了102例连续的新诊断肺癌患者（平均年龄65.2±11岁）（96例男性，占94%，平均年龄66.3±10.5岁）。所有患者均进行了5年随访。在初次诊断时对血清肿瘤标志物进行检测。
84例患者（82%）患有非小细胞肺癌（NSCLC），18例（18%）患有小细胞肺癌（SCLC）。在84例NSCLC患者中，34例（33%）为鳞状细胞肺癌，23例（22%）为腺癌，23例（22%）为大细胞癌。总体中位生存期为8.5个月。所有SCLC患者均为广泛期疾病，中位生存期为10.1个月，NSCLC患者为8.4个月。SCLC和NSCLC之间NSE和CYFRA 21-1的平均值存在显著差异。在NSCLC中，CYFRA 21-1、TPA、CA 125和SCCAg血清水平与诊断时疾病分期相关，CYFRA 21-1、NSE、TPA和CA-125与不良预后相关。上述肿瘤标志物在SCLC组中均与生存期无关。
CYFRA 21-1和NSE可能有助于区分肺癌患者的细胞类型。此外，CYFRA 21-1联合TPA和CA 125可能为NSCLC患者诊断时疾病分期及预后提供有用信息。
Zotero 插件